Skip to main content
Fig. 5 | Breast Cancer Research

Fig. 5

From: High B3GALT5 expression confers poor clinical outcome and contributes to tumor progression and metastasis in breast cancer

Fig. 5

Knockdown or overexpression of B3GALT5 altered cell proliferation, morphology and expression of ZEB1 and β-catenin. a AS-B634 cells were transfected with control siRNA (si-Ctrl) or B3GALT5 siRNA (si-B3GALT-1 and si-B3GALT-2) and cultured for 5 days. Cell numbers were counted every day. b Phase contrast photographs of AS-B634 cells transfected with control siRNA (si-Ctrl) or B3GALT5 siRNA (si-B3GALT5-1) and MDA-MB-231 cells transfected with vector control plasmids (Ctrl) or B3GALT5 overexpression plasmids (OE). Scale bar 50 μm. c ZEB1 expression in AS-B634 and MDA-MB-231 as determined by western blotting. The expression of ZEB1 was normalized to actin and presented as relative fold change. d Cytoplasmic and nuclear ZEB1 and active β-catenin expression in AS-B634 and MDA-MB-231 as determined by western blotting. The expression of cytoplasmic or nuclear ZEB1 and active β-catenin was normalized to GAPDH or Histone 1, respectively, and presented as relative fold change. e–g MDA-MB-231 B3GALT5 overexpressing cells (OE) were transfected with control siRNA (si-Ctrl), si-ZEB1-1 or si-ZEB1-2 (e). Migration (f) and invasion (g) assays were performed. f, g Data were shown as mean ± SD. ****P < 0.0001, **P < 0.01 by t test. Three independent experiments were performed in each study

Back to article page